The Society for Immunotherapy of Cancer (SITC) hosted Session 103 during the 39th Annual Meeting & Pre-Conference Programs on Friday, November 8, 2024. Available here are the presentation slides and video from “Session 103: Pre-malignancy Biology Driving Precision Prevention and Interception Immunotherapy” as permitted by presenters.
Olivera Finn, PhD, FAIO – University of Pittsburgh
Many important discoveries in immunology over the last several decades have been applied to the cancer problem with the goal of making immune rejection of cancer more effective. This knowledge has resulted in the development of highly effective cancer immunotherapies for patients with advanced disease. Relatively little of this knowledge has translated into efforts to strengthen cancer immunosurvellance to prevent or intercept cancer development. Vaccines have successfully prevented virus-associated cancers including cervical and hepatocellular carcinomas. At this time of rising cancer rates in young adults, vaccines targeting the earliest changes in premalignacy are urgently needed. This session will highlight research leading us in this new direction.
To view the entire program schedule (including presenter permission to post) please click here.
02:10:12